Centessa Pharmaceuticals plc Logo

Centessa Pharmaceuticals plc

Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.

CNTA | US

Overview

Corporate Details

ISIN(s):
US1523091007
LEI:
Country:
United States of America
Address:
3RD FLOOR, ALTRINCHAM, CHESHIRE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients with unmet medical needs. The company leverages a data-driven Research & Development model to advance a portfolio of innovative assets. Its lead program is a potential best-in-class orexin receptor 2 (OX2R) agonist being developed for the treatment of sleep-wake disorders. The company's pipeline also includes programs targeting other conditions, such as hemophilia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Centessa Pharmaceuticals plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Centessa Pharmaceuticals plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Centessa Pharmaceuticals plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America IMMX
IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea 424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan 4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America IMRN

Talk to a Data Expert

Have a question? We'll get back to you promptly.